Raising the Stakes On Value-Based Pricing
[...]pharmaceutical manufacturers will increasingly need to demonstrate value to global payers and health technology assessment (HTA) bodies as a prerequisite for premium prices and/or significant price increases. Together with other conventional pharmaceutical company offerings (e.g., disease manag...
Gespeichert in:
| Veröffentlicht in: | Pharmaceutical Executive 2016-04, Vol.36 (4), p.46 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 46 |
| container_title | Pharmaceutical Executive |
| container_volume | 36 |
| creator | Parece, Andrew Wiedemann, Urs |
| description | [...]pharmaceutical manufacturers will increasingly need to demonstrate value to global payers and health technology assessment (HTA) bodies as a prerequisite for premium prices and/or significant price increases. Together with other conventional pharmaceutical company offerings (e.g., disease management program support and caredelivery "hub" services), these arrangements have the potential to change the dialogue between manufacturers and payers, from price to value. [...]the industry consistently provides solutions to reinforce the value of new therapies, consumers, payers, and politicians will continue to focus on the cost side of the equation, applying price caps and arbitrary access "austerity" measures that do not recognize or reward innovation. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_reports_1781501111</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4025610341</sourcerecordid><originalsourceid>FETCH-proquest_reports_17815011113</originalsourceid><addsrcrecordid>eNpjYuA0MjQ10DU3No1gYeA0MDK31DUzNTfgYOAqLs4yMDAwMTG14GTQDErMLM7MS1coyUhVCC5JzE4tVvDPUwhLzClN1XVKLE5NUQgoykwGquBhYE1LzClO5YXS3AxKbq4hzh66BUX5haWpxSXxRakF-UUlxfGG5hZAmw2BwJgoRQADIzA1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1781501111</pqid></control><display><type>article</type><title>Raising the Stakes On Value-Based Pricing</title><source>Business Source Complete</source><creator>Parece, Andrew ; Wiedemann, Urs</creator><creatorcontrib>Parece, Andrew ; Wiedemann, Urs</creatorcontrib><description>[...]pharmaceutical manufacturers will increasingly need to demonstrate value to global payers and health technology assessment (HTA) bodies as a prerequisite for premium prices and/or significant price increases. Together with other conventional pharmaceutical company offerings (e.g., disease management program support and caredelivery "hub" services), these arrangements have the potential to change the dialogue between manufacturers and payers, from price to value. [...]the industry consistently provides solutions to reinforce the value of new therapies, consumers, payers, and politicians will continue to focus on the cost side of the equation, applying price caps and arbitrary access "austerity" measures that do not recognize or reward innovation.</description><identifier>ISSN: 0279-6570</identifier><identifier>EISSN: 2150-735X</identifier><language>eng</language><publisher>Monmouth Junction: MultiMedia Healthcare Inc</publisher><subject>Agreements ; Clinical outcomes ; Costs ; Drug prices ; Funding ; Guarantees ; Inflation ; Infrastructure ; Pharmaceutical industry ; Pharmacy ; Prescription drugs ; Price increases ; Risk exposure ; Risk sharing ; Wage & price controls</subject><ispartof>Pharmaceutical Executive, 2016-04, Vol.36 (4), p.46</ispartof><rights>Copyright Advanstar Communications, Inc. Apr 2016</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>312,780,784,791</link.rule.ids></links><search><creatorcontrib>Parece, Andrew</creatorcontrib><creatorcontrib>Wiedemann, Urs</creatorcontrib><title>Raising the Stakes On Value-Based Pricing</title><title>Pharmaceutical Executive</title><description>[...]pharmaceutical manufacturers will increasingly need to demonstrate value to global payers and health technology assessment (HTA) bodies as a prerequisite for premium prices and/or significant price increases. Together with other conventional pharmaceutical company offerings (e.g., disease management program support and caredelivery "hub" services), these arrangements have the potential to change the dialogue between manufacturers and payers, from price to value. [...]the industry consistently provides solutions to reinforce the value of new therapies, consumers, payers, and politicians will continue to focus on the cost side of the equation, applying price caps and arbitrary access "austerity" measures that do not recognize or reward innovation.</description><subject>Agreements</subject><subject>Clinical outcomes</subject><subject>Costs</subject><subject>Drug prices</subject><subject>Funding</subject><subject>Guarantees</subject><subject>Inflation</subject><subject>Infrastructure</subject><subject>Pharmaceutical industry</subject><subject>Pharmacy</subject><subject>Prescription drugs</subject><subject>Price increases</subject><subject>Risk exposure</subject><subject>Risk sharing</subject><subject>Wage & price controls</subject><issn>0279-6570</issn><issn>2150-735X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpjYuA0MjQ10DU3No1gYeA0MDK31DUzNTfgYOAqLs4yMDAwMTG14GTQDErMLM7MS1coyUhVCC5JzE4tVvDPUwhLzClN1XVKLE5NUQgoykwGquBhYE1LzClO5YXS3AxKbq4hzh66BUX5haWpxSXxRakF-UUlxfGG5hZAmw2BwJgoRQADIzA1</recordid><startdate>20160401</startdate><enddate>20160401</enddate><creator>Parece, Andrew</creator><creator>Wiedemann, Urs</creator><general>MultiMedia Healthcare Inc</general><scope>0U~</scope><scope>1-H</scope><scope>3V.</scope><scope>7RV</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>883</scope><scope>88C</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>KB0</scope><scope>L.-</scope><scope>L.0</scope><scope>M0C</scope><scope>M0F</scope><scope>M0S</scope><scope>M0T</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20160401</creationdate><title>Raising the Stakes On Value-Based Pricing</title><author>Parece, Andrew ; Wiedemann, Urs</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_reports_17815011113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Agreements</topic><topic>Clinical outcomes</topic><topic>Costs</topic><topic>Drug prices</topic><topic>Funding</topic><topic>Guarantees</topic><topic>Inflation</topic><topic>Infrastructure</topic><topic>Pharmaceutical industry</topic><topic>Pharmacy</topic><topic>Prescription drugs</topic><topic>Price increases</topic><topic>Risk exposure</topic><topic>Risk sharing</topic><topic>Wage & price controls</topic><toplevel>online_resources</toplevel><creatorcontrib>Parece, Andrew</creatorcontrib><creatorcontrib>Wiedemann, Urs</creatorcontrib><collection>Global News & ABI/Inform Professional</collection><collection>Trade PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>ABI/INFORM Trade & Industry (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Professional Standard</collection><collection>ABI/INFORM Global</collection><collection>ABI/INFORM Trade & Industry</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>One Business (ProQuest)</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>Pharmaceutical Executive</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Parece, Andrew</au><au>Wiedemann, Urs</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Raising the Stakes On Value-Based Pricing</atitle><jtitle>Pharmaceutical Executive</jtitle><date>2016-04-01</date><risdate>2016</risdate><volume>36</volume><issue>4</issue><spage>46</spage><pages>46-</pages><issn>0279-6570</issn><eissn>2150-735X</eissn><abstract>[...]pharmaceutical manufacturers will increasingly need to demonstrate value to global payers and health technology assessment (HTA) bodies as a prerequisite for premium prices and/or significant price increases. Together with other conventional pharmaceutical company offerings (e.g., disease management program support and caredelivery "hub" services), these arrangements have the potential to change the dialogue between manufacturers and payers, from price to value. [...]the industry consistently provides solutions to reinforce the value of new therapies, consumers, payers, and politicians will continue to focus on the cost side of the equation, applying price caps and arbitrary access "austerity" measures that do not recognize or reward innovation.</abstract><cop>Monmouth Junction</cop><pub>MultiMedia Healthcare Inc</pub></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0279-6570 |
| ispartof | Pharmaceutical Executive, 2016-04, Vol.36 (4), p.46 |
| issn | 0279-6570 2150-735X |
| language | eng |
| recordid | cdi_proquest_reports_1781501111 |
| source | Business Source Complete |
| subjects | Agreements Clinical outcomes Costs Drug prices Funding Guarantees Inflation Infrastructure Pharmaceutical industry Pharmacy Prescription drugs Price increases Risk exposure Risk sharing Wage & price controls |
| title | Raising the Stakes On Value-Based Pricing |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A07%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Raising%20the%20Stakes%20On%20Value-Based%20Pricing&rft.jtitle=Pharmaceutical%20Executive&rft.au=Parece,%20Andrew&rft.date=2016-04-01&rft.volume=36&rft.issue=4&rft.spage=46&rft.pages=46-&rft.issn=0279-6570&rft.eissn=2150-735X&rft_id=info:doi/&rft_dat=%3Cproquest%3E4025610341%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1781501111&rft_id=info:pmid/&rfr_iscdi=true |